Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

661.80INR
9:47am BST
Change (% chg)

Rs16.20 (+2.51%)
Prev Close
Rs645.60
Open
Rs644.00
Day's High
Rs665.80
Day's Low
Rs643.00
Volume
1,585,862
Avg. Vol
2,815,599
52-wk High
Rs678.45
52-wk Low
Rs507.20

Latest Key Developments (Source: Significant Developments)

Cipla Gets Final Approval For Generic Reyataz
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Cipla Ltd ::CIPLA RECEIVES FINAL APPROVAL FOR GENERIC REYATAZ.DRUG INDICATED FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR TREATMENT OF HIV-1 INFECTION.  Full Article

U.S. FDA Assigns Voluntary Action Status To Cipla's Indore Unit - ET Now, Citing Cogencis
Friday, 6 Jul 2018 

July 6 (Reuters) - :U.S. FDA ASSIGNS VOLUNTARY ACTION STATUS TO CIPLA LTD'S INDORE UNIT - ET NOW, CITING COGENCIS.  Full Article

Cipla Gets Final Approval For Generic Depo-Testosterone From U.S. FDA
Thursday, 21 Jun 2018 

June 21 (Reuters) - Cipla Ltd ::SAYS CO RECEIVED FINAL APPROVAL FOR ANDA FOR TESTOSTERONE CYPIONATE INJECTION 100MG/ML AND 200MG/ML FROM U.S. FDA.  Full Article

India's Cipla Gets Final Nod From U.S FDA For Efavirenz Tablets
Tuesday, 19 Jun 2018 

June 19 (Reuters) - Cipla Ltd ::SAYS GOT FINAL APPROVAL FOR ITS ABBREVIATED NEW DRUG APPLICATION (ANDA) FOR EFAVIRENZ TABLETS 600MG FROM USFDA.DRUG INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION.  Full Article

India's Cipla Ltd Posts March Qtr Consol Profit
Tuesday, 22 May 2018 

May 22 (Reuters) - Cipla Ltd ::MARCH QUARTER CONSOL NET PROFIT 1.79 BILLION RUPEES VERSUS LOSS OF 617.9 MILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL NET PROFIT WAS 3.57 BILLION RUPEES.MARCH QUARTER CONSOL NET SALES 34.96 BILLION RUPEES VERSUS 34.87 BILLION RUPEES LAST YEAR.RECOMMENDED DIVIDEND OF 3 RUPEES PER SHARE.SAYS MARCH QUARTER CONSOL EXCEPTIONAL ITEM OF 775.2 MILLION RUPEES.  Full Article

Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India
Wednesday, 9 May 2018 

May 9 (Reuters) - Cipla Ltd ::MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA.MANNKIND - UNDER TERMS OF AGREEMENT, CIPLA WILL BE RESPONSIBLE FOR OBTAINING REGULATORY APPROVALS TO DISTRIBUTE AFREZZA IN INDIA.MANNKIND CORP - EXCLUSIVE MARKETING & DISTRIBUTION DEAL FOR AFREZZA IN INDIA WITH CIPLA LTD.MANNKIND CORP - CIPLA WILL ALSO BE RESPONSIBLE FOR ALL MARKETING AND SALES ACTIVITIES OF AFREZZA IN INDIA.MANNKIND CORP - MANNKIND IS RESPONSIBLE FOR SUPPLYING AFREZZA TO CIPLA.MANNKIND CORP - MANNKIND WILL RECEIVE A $2.2 MILLION UPFRONT PAYMENT FROM CIPLA WITHIN 30 DAYS OF ENTERING AGREEMENT.  Full Article

India's Cipla Gets Final Nod For Generic Vazculep, Others
Wednesday, 2 May 2018 

May 2 (Reuters) - Cipla Ltd ::GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN.PRODUCTS ARE MANUFACTURED AT CO'S GOA PLANT.  Full Article

Cipla's JV Saba Investment Completes Disinvestment Of Stake Held In Al Jabal For Drugs And Medical Appliances
Monday, 26 Mar 2018 

March 26 (Reuters) - Cipla Ltd ::CO'S JV SABA INVESTMENT COMPLETED DISINVESTMENT OF 99 PERCENT STAKE HELD IN AL JABAL FOR DRUGS AND MEDICAL APPLIANCES CO.  Full Article

India's Cipla Says Unit Launches Authorized Generic Version Of Aloxi In U.S.
Monday, 26 Mar 2018 

March 26 (Reuters) - Cipla Ltd ::SAYS ‍CO'S UNIT LAUNCHES AUTHORIZED GENERIC VERSION OF ALOXI IN U.S..  Full Article

Kiadis Pharma Proposes Subhanu Saxena, Former Cipla CEO, As New Supervisory Board Member
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - KIADIS PHARMA NV ::KIADIS PHARMA PROPOSES FORMER CIPLA CEO SUBHANU SAXENA AS NEW SUPERVISORY BOARD MEMBER.SUPERVISORY BOARD WILL NOMINATE SUBHANU SAXENA TO BE APPOINTED AS NEW MEMBER OF SUPERVISORY BOARD​.  Full Article

CORRECTED-Ugandan unit of Indian drugs firm Cipla raises $43.8 mln in IPO - Renaissance Capital

KAMPALA, Sept 17 The Ugandan unit of India's pharmaceutical giant Cipla raised 167 billion Ugandan shillings ($43.8 million) from its oversubscribed initial public offering (IPO), an investment bank that helped advise on the transaction said on Monday.